Copy to clipboard 
Osteopore signed an exclusive license with Accelerate for a bioactive technology platform, Heparan Sulphate, designed to accelerate bone and tissue regeneration.
Osteopore has been working with the Institute of Molecular and Cell Biology (IMCB) to incorporate various types of Heparan Sulphate with Osteopore’s technology. This combination has the potential to provide unprecedented clinical outcomes by significantly improving the rate and quality of bone regeneration, leading to faster recovery times, reduced complications, and improved overall patient health.
In 2024, Osteopore initiated a human clinical trial at the National University Hospital Singapore combining Heparan Sulphate 3 (HS3), a molecule targeting bone morphogenetic protein-2 (BMP-2), with Osteopore’s regulatory-approved product for the treatment of medial wedge opening High Tibial Osteotomy in up to 12 patients. This clinical study is in progress.
The exclusive license for the Heparan Sulphate technology covers two families of Heparan Sulphate (including HS3) for all life science and medical use, research and clinical use, including patents and know-how. The countries covered by the exclusive license include the United States, the European Union, and China.
This license spans a 15-year period and provides for an upfront payment, royalties linked to sales, and additional payments upon the achievement of market approval milestones. Whilst the specific financial terms are confidential, the company advises that it does not
anticipate the license arrangement to have an immediate or short-term material impact on its operating results.
Commenting on the exclusive licensing agreement, CEO Dr Yujing Lim said, “We are delighted to onboard an important innovative platform technology that strengthens Osteopore’s position in regenerative medicine. This new technology platform has the potential to challenge current treatment options due to its enhanced safety profile and stronger consistency of results. The territory covered by the patents and knowhow aligns with our expansion strategy, and is an exciting addition to our technology and future product portfolio. We are now entering the early stages of commercialising this technology, and will undertake the process in line with current regulatory requirements.”
Source: Osteopore
Osteopore signed an exclusive license with Accelerate for a bioactive technology platform, Heparan Sulphate, designed to accelerate bone and tissue regeneration.
Osteopore has been working with the Institute of Molecular and Cell Biology (IMCB) to incorporate various types of Heparan Sulphate with Osteopore’s technology. This combination has...
Osteopore signed an exclusive license with Accelerate for a bioactive technology platform, Heparan Sulphate, designed to accelerate bone and tissue regeneration.
Osteopore has been working with the Institute of Molecular and Cell Biology (IMCB) to incorporate various types of Heparan Sulphate with Osteopore’s technology. This combination has the potential to provide unprecedented clinical outcomes by significantly improving the rate and quality of bone regeneration, leading to faster recovery times, reduced complications, and improved overall patient health.
In 2024, Osteopore initiated a human clinical trial at the National University Hospital Singapore combining Heparan Sulphate 3 (HS3), a molecule targeting bone morphogenetic protein-2 (BMP-2), with Osteopore’s regulatory-approved product for the treatment of medial wedge opening High Tibial Osteotomy in up to 12 patients. This clinical study is in progress.
The exclusive license for the Heparan Sulphate technology covers two families of Heparan Sulphate (including HS3) for all life science and medical use, research and clinical use, including patents and know-how. The countries covered by the exclusive license include the United States, the European Union, and China.
This license spans a 15-year period and provides for an upfront payment, royalties linked to sales, and additional payments upon the achievement of market approval milestones. Whilst the specific financial terms are confidential, the company advises that it does not
anticipate the license arrangement to have an immediate or short-term material impact on its operating results.
Commenting on the exclusive licensing agreement, CEO Dr Yujing Lim said, “We are delighted to onboard an important innovative platform technology that strengthens Osteopore’s position in regenerative medicine. This new technology platform has the potential to challenge current treatment options due to its enhanced safety profile and stronger consistency of results. The territory covered by the patents and knowhow aligns with our expansion strategy, and is an exciting addition to our technology and future product portfolio. We are now entering the early stages of commercialising this technology, and will undertake the process in line with current regulatory requirements.”
Source: Osteopore
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
